Premium
Hormone replacement therapy
Author(s) -
John C. Stevenson,
M. I. Whitehead
Publication year - 1993
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(93)90709-6
Subject(s) - medicine , medroxyprogesterone acetate , hormone replacement therapy (female to male) , hormone therapy , medroxyprogesterone , quality of life (healthcare) , life expectancy , hormone , menopause , gynecology , endometrial biopsy , obstetrics , endometrium , population , breast cancer , cancer , testosterone (patch) , nursing , environmental health
All patients receiving hormone replacement therapy should be evaluated annually. During these evaluations, breast and pelvic examinations should be performed and a Pap smear taken, and attention should be directed to cholesterol, blood pressure, and the effectiveness of treatment. In women given adequate progestins (medroxyprogesterone acetate, 10 mg each day for 12 days a month), endometrial biopsy should be reserved for women with clinical problems such as excessive or prolonged bleeding. In women taking no progestins, pretreatment and yearly biopsies are required. In addition, annual mammograms should be obtained on women over the age of 50. Hormone replacement therapy, although not suited to all patients, can confer health benefits, enhance quality of life, and prolong life expectancy (46).